Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome

Sex: All

Ages: 18 Years – 100 Years

Healthy volunteers: No

Phase: PHASE1

Enrollment: 5

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Summary

This correlative study aims to understand the pharmacodynamic effects and clonal dynamics in response to epcoritamab by obtaining and analyzing lymph node, bone marrow, and blood samples from subjects enrolled in GCT3013-03 trial sponsored by Genmab at NIH. Samples will be collected before and at multiple time points during treatment with epcoritamab. National Heart, Lung, and Blood Institute (NHLBI) investigators are experienced in testing samples treated with bsAb2,3 including epcoritamab in an ongoing pre-clinical collaboration with Genmab. Addressing the objectives of this correlative study will advance the science and clinical application of epcoritamab specifically as well as T-cell engaging bsAb in general as an emerging class of immunotherapy for cancer. The study is enrolling by invitation only.

Eligibility Criteria

* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Must be undergoing screening for GCT3013-03 * Stated willingness to comply with all study procedures and availability for the duration of the study * Ability of subject to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA: None

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06676033). StuddyBuddy aggregates publicly available trial information.